Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03400371 · ClinicalTrials.gov registry record
Biology of Juvenile Myoclonic Epilepsy
A clinical trial of Juvenile Myoclonic Epilepsy, sponsored by King's College London.
- Recruiting
- Registry status
- 1,000
- Enrollment target
- 15
- Study locations
NCT03400371: Recruiting study of Juvenile Myoclonic Epilepsy, sponsored by King's College London.
NCT03400371 is a study of Juvenile Myoclonic Epilepsy that is actively recruiting participants, run by King's College London. The registered enrollment target is 1,000 participants. The trial reports 15 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03400371, a study of Juvenile Myoclonic Epilepsy, is actively recruiting participants, sponsored by King's College London.
- RECRUITING
- Registry status
- 1,000 participants
- Enrollment target
- 15
- Study locations
Study Summary
The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be compared to anonymised data from samples for 2000 controls. The goal of this study is to find the genetic cause of JME. Finding the cause will help create better treatments for JME, as well as improve patient outcomes by allowing us to detect it earlier.
Primary Outcome
Association between SNP marker and phenotype is measured using genomewide DNA markers, which enables us to test support for molecular networks that act on seizure susceptibility
Conditions Studied
Interventions
- OTHER Blood draw
- OTHER Existing samples
Study Locations (15)
Other
- Charles University - Prague
- Danish National Epilepsy Centre - Dianalund
- Tallinn Children's Hospital - Tallinn
- University Robert Debré - Paris
- Commissione Genetica Lega Italiana contro l'Epilepssia - Roma
- Vestre Viken Health Trust, Oslo - Drammen
- Walton Centre for Neurology and Neurosurgery - Liverpool
- Royal London Hospital - London
- St Thomas' Hospital - London
- King's College Hospital NHS Trust - London
- Swansea University - Swansea
New York
- Mount Sinai-Beth Israel Medical Center - New York
- St Luke's Roosevelt Hospital - New York
Ohio
- Nationwide Children's Hospital - Columbus
Ontario
- Hospital for Sick Kids - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2017-07-13 |
| Est. Completion | 2026-12-31 |
What NCT03400371 shows while recruiting
NCT03400371 is an observational study that tracks outcomes without assigning an intervention. Its 1,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Juvenile Myoclonic Epilepsy appearing as the primary indexed condition, and to 2 interventions - of which Blood draw is the first listed.
NCT03400371 lists 15 locations in 4 states (Other, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT03400371 about?
NCT03400371 is a clinical study titled "Biology of Juvenile Myoclonic Epilepsy". The investigators are collecting genetic information through blood samples as well as clinical and EEG data from over 1000 people with Juvenile Myoclonic Epilepsy (JME) across the UK, Europe and North America. This study will draw on both existing and new samples from JME patients. These will be com...
What is the current status of trial NCT03400371?
This trial is currently recruiting. The enrollment target is 1,000 participants. The study started on 2017-07-13. Estimated completion is 2026-12-31.
What conditions does trial NCT03400371 study?
This clinical trial studies the following conditions: Juvenile Myoclonic Epilepsy.
What interventions are being tested in trial NCT03400371?
The interventions under investigation include: Blood draw (OTHER), Existing samples (OTHER).
Who is sponsoring clinical trial NCT03400371?
This trial is sponsored by King's College London, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03400371 being conducted?
This trial has 15 study locations across New York, Ohio, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
- NCT01192048 · 1,000 participants
Genetics of Congenital Heart Disease
- NCT01553214 · 1,000 participants · Phase 4
Improving White Blood Cell Collection From Healthy Donors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI